Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Civitas chooses $525mm acquisition by Acorda over IPO

Executive Summary

Acorda Therapeutics Inc. (neuromuscular and cardiovascular diseases) paid $525mm in cash for private drug delivery company Civitas Therapeutics Inc., which has abandoned its plans to go public (the company filed an S-1 in August). The purchase price includes $35mm tied to a Civitas change-in-control provision.

Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register